SE0002353D0 - New use - Google Patents

New use

Info

Publication number
SE0002353D0
SE0002353D0 SE0002353A SE0002353A SE0002353D0 SE 0002353 D0 SE0002353 D0 SE 0002353D0 SE 0002353 A SE0002353 A SE 0002353A SE 0002353 A SE0002353 A SE 0002353A SE 0002353 D0 SE0002353 D0 SE 0002353D0
Authority
SE
Sweden
Prior art keywords
vascular headache
new use
treatment
condition
angiotensin
Prior art date
Application number
SE0002353A
Other languages
English (en)
Swedish (sv)
Inventor
Harald Schrader
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0002353A priority Critical patent/SE0002353D0/xx
Publication of SE0002353D0 publication Critical patent/SE0002353D0/xx
Priority to IL15315801A priority patent/IL153158A0/xx
Priority to SI200130524T priority patent/SI1307192T1/sl
Priority to BR0111900-1A priority patent/BR0111900A/pt
Priority to PT01941408T priority patent/PT1307192E/pt
Priority to CNB018142788A priority patent/CN1250218C/zh
Priority to PCT/SE2001/001379 priority patent/WO2001097807A1/en
Priority to AU7476501A priority patent/AU7476501A/xx
Priority to NZ523048A priority patent/NZ523048A/en
Priority to JP2002503291A priority patent/JP2003535897A/ja
Priority to CNA2006100088164A priority patent/CN1846697A/zh
Priority to AT01941408T priority patent/ATE318597T1/de
Priority to DK01941408T priority patent/DK1307192T3/da
Priority to CA002411553A priority patent/CA2411553A1/en
Priority to US10/311,760 priority patent/US7872035B2/en
Priority to KR1020027017396A priority patent/KR100692235B1/ko
Priority to AU2001274765A priority patent/AU2001274765B2/en
Priority to EP01941408A priority patent/EP1307192B1/en
Priority to DE60117541T priority patent/DE60117541T2/de
Priority to EP05028367A priority patent/EP1656940A1/en
Priority to ES01941408T priority patent/ES2257416T3/es
Priority to MXPA02012574A priority patent/MXPA02012574A/es
Priority to IL153158A priority patent/IL153158A/en
Priority to ZA200209902A priority patent/ZA200209902B/en
Priority to NO20026085A priority patent/NO330300B1/no
Priority to HK03105920A priority patent/HK1053609A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Mattresses And Other Support Structures For Chairs And Beds (AREA)
SE0002353A 2000-06-22 2000-06-22 New use SE0002353D0 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE0002353A SE0002353D0 (sv) 2000-06-22 2000-06-22 New use
MXPA02012574A MXPA02012574A (es) 2000-06-22 2001-06-15 Uso novedoso de los antagonistas ii de angiotensina.
DK01941408T DK1307192T3 (da) 2000-06-22 2001-06-15 Candesartan til behandling af migræne
US10/311,760 US7872035B2 (en) 2000-06-22 2001-06-15 Angiotensin II antagonists
BR0111900-1A BR0111900A (pt) 2000-06-22 2001-06-15 Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
PT01941408T PT1307192E (pt) 2000-06-22 2001-06-15 Candesartan para tratamento da enxaqueca
CNB018142788A CN1250218C (zh) 2000-06-22 2001-06-15 血管紧张素拮ⅱ抗剂的新用途
PCT/SE2001/001379 WO2001097807A1 (en) 2000-06-22 2001-06-15 New use of angiotensin ii antagonists
AU7476501A AU7476501A (en) 2000-06-22 2001-06-15 New use of angiotensin ii antagonists
NZ523048A NZ523048A (en) 2000-06-22 2001-06-15 Use of angiotensin II antagonists for treating vascular headache not caused by hypertension
JP2002503291A JP2003535897A (ja) 2000-06-22 2001-06-15 アンギオテンシンｉｉアンタゴニストの新規使用法
CNA2006100088164A CN1846697A (zh) 2000-06-22 2001-06-15 血管紧张素ⅱ拮抗剂的新用途
AT01941408T ATE318597T1 (de) 2000-06-22 2001-06-15 Candesartan zur behandlung von migräne
IL15315801A IL153158A0 (en) 2000-06-22 2001-06-15 New use of angiotensin ii antagonists
CA002411553A CA2411553A1 (en) 2000-06-22 2001-06-15 New use of angiotensin ii antagonists
SI200130524T SI1307192T1 (sl) 2000-06-22 2001-06-15 Kandesartan za zdravljenje migrene
KR1020027017396A KR100692235B1 (ko) 2000-06-22 2001-06-15 안지오텐신 ⅱ 길항물질의 신규한 용도
AU2001274765A AU2001274765B2 (en) 2000-06-22 2001-06-15 New use of angiotensin II antagonists
EP01941408A EP1307192B1 (en) 2000-06-22 2001-06-15 Candesartan for treating migraine
DE60117541T DE60117541T2 (de) 2000-06-22 2001-06-15 Candesartan zur Behandlung von Migräne
EP05028367A EP1656940A1 (en) 2000-06-22 2001-06-15 Angiotensin II receptor antagonists for treating vascular headache conditions
ES01941408T ES2257416T3 (es) 2000-06-22 2001-06-15 Candesartan para tratar la migraña.
IL153158A IL153158A (en) 2000-06-22 2002-11-28 New use of type 1 angiotensin II antagonists in the manufacture of a drug for the prophylactic and / or therapeutic treatment of vascular headaches that are not caused by hypertension
ZA200209902A ZA200209902B (en) 2000-06-22 2002-12-05 New use of angiotensin II antagonists.
NO20026085A NO330300B1 (no) 2000-06-22 2002-12-18 Anvendelse av angiotensin II-antagonister for fremstilling av medikamenter for behandling av sykdom
HK03105920A HK1053609A1 (en) 2000-06-22 2003-08-19 Candesartan for treating migraine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002353A SE0002353D0 (sv) 2000-06-22 2000-06-22 New use

Publications (1)

Publication Number Publication Date
SE0002353D0 true SE0002353D0 (sv) 2000-06-22

Family

ID=20280208

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002353A SE0002353D0 (sv) 2000-06-22 2000-06-22 New use

Country Status (21)

Country Link
US (1) US7872035B2 (zh)
EP (2) EP1307192B1 (zh)
JP (1) JP2003535897A (zh)
KR (1) KR100692235B1 (zh)
CN (2) CN1250218C (zh)
AT (1) ATE318597T1 (zh)
AU (2) AU2001274765B2 (zh)
BR (1) BR0111900A (zh)
CA (1) CA2411553A1 (zh)
DE (1) DE60117541T2 (zh)
DK (1) DK1307192T3 (zh)
ES (1) ES2257416T3 (zh)
HK (1) HK1053609A1 (zh)
IL (2) IL153158A0 (zh)
MX (1) MXPA02012574A (zh)
NO (1) NO330300B1 (zh)
NZ (1) NZ523048A (zh)
PT (1) PT1307192E (zh)
SE (1) SE0002353D0 (zh)
WO (1) WO2001097807A1 (zh)
ZA (1) ZA200209902B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356815A4 (en) * 2001-01-29 2007-03-07 Takeda Pharmaceutical ANALGESIC AND ANTI-INFLAMMATORY DRUGS
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
FR2892803B1 (fr) 2005-10-28 2008-04-04 Valeo Systemes Thermiques Boite collectrice pour echangeur de chaleur, notamment pour evaporateur de climatisation, echangeur comportant une telle boite
JP5468420B2 (ja) * 2010-03-04 2014-04-09 株式会社マキタ 手持ち式切断工具
WO2012135597A2 (en) * 2011-03-30 2012-10-04 The Johns Hopkins University Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair
KR20130074808A (ko) 2011-12-16 2013-07-05 한올바이오파마주식회사 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5241009A (en) 1990-05-07 1993-08-31 Kimberly-Clark Corporation Polymeric composition containing carboxy nueutralized with lithium or potassium
CA2041763A1 (en) * 1990-05-11 1991-11-12 Sheih-Shung T. Chen Microbial transformation process for antihypertensive products
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5214153A (en) 1992-04-23 1993-05-25 Merck & Co., Inc. Actinoplanes transformation process anti-hypertensive compound and method of use thereas

Also Published As

Publication number Publication date
HK1053609A1 (en) 2003-10-31
PT1307192E (pt) 2006-06-30
EP1307192B1 (en) 2006-03-01
DK1307192T3 (da) 2006-06-12
CN1447693A (zh) 2003-10-08
NZ523048A (en) 2004-09-24
DE60117541T2 (de) 2006-09-14
WO2001097807A1 (en) 2001-12-27
NO20026085D0 (no) 2002-12-18
EP1656940A1 (en) 2006-05-17
IL153158A0 (en) 2003-06-24
CN1250218C (zh) 2006-04-12
AU2001274765B2 (en) 2005-08-18
AU7476501A (en) 2002-01-02
IL153158A (en) 2008-03-20
DE60117541D1 (de) 2006-04-27
NO20026085L (no) 2002-12-18
EP1307192A1 (en) 2003-05-07
NO330300B1 (no) 2011-03-28
KR20030019444A (ko) 2003-03-06
US20040092563A1 (en) 2004-05-13
CN1846697A (zh) 2006-10-18
ATE318597T1 (de) 2006-03-15
ZA200209902B (en) 2004-03-05
BR0111900A (pt) 2003-05-13
US7872035B2 (en) 2011-01-18
JP2003535897A (ja) 2003-12-02
ES2257416T3 (es) 2006-08-01
MXPA02012574A (es) 2003-04-10
CA2411553A1 (en) 2001-12-27
KR100692235B1 (ko) 2007-03-09

Similar Documents

Publication Publication Date Title
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
GB0005251D0 (en) Therapeutic compounds
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
JO2371B1 (en) 4-phenyl-pyridine derivatives
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
WO2004091514A3 (en) Cgrp receptor antagonists
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
SE0101932D0 (sv) Pharmaceutical combinations
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE0102055D0 (sv) New Compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
SE0002353D0 (sv) New use
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
SE9902597D0 (sv) New use
BR0206687A (pt) Método para prevenir e tratar dores viscerais e distúrbios gastrointestinais
SE0203349D0 (sv) New use
DE60143671D1 (de) Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
DE50214537D1 (de) C2-disubstituierte indan-1-one und ihre derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel